• BURN MEDIA
    • Memeburn
      Tech-savvy insight and analysis
    • Gearburn
      Incisive reviews for the gadget obsessed
    • Motorburn
      Because cars are gadgets
    • Jobsburn
      Digital industry jobs for the anti 9 to 5!

All posts by Kevin Xu

Kevin Xu
Kevin Xu is the CEO of MEBO International, a California- and Beijing-based intellectual property management company specializing in applied health systems. He also leads Skingenix, which specializes in skin organ regeneration and the research and development of botanical drug products. Kevin is co-founder of the Human Heritage Project.
  • 3 things to consider before expanding into China

    Trust. That's the No. 1 reason customers try out new stores according to a joint report by Retail Week and international law firm Pinsent Masons. Now, think about asking customers in a different corner of the world to buy what you're selling. Trust, then, becomes an even bigger selling point. For many entrepreneurs, expanding internationally is just a matter of logistics. Setting up a business location, hiring employees, getting a production chain going, finding people who know the language -- these are considered chief difficulties when moving your business to another part of the globe. However, the entrepreneurs who think this...

  • Biosimilars: the next great biotech investment?

    Entrepreneurs are all about disruption. As crowded as many industries have become with thousands of startups competing for market share, one area still has a curiously high ratio of opportunity to competitors: biotechnology. Even more interesting, the advent of biosimilars and the wave of patents on their production set to expire before 2020 — worth about $67 billion — indicate that biotech startups are about to have a lot more room to expand. What Are Biosimilars? Biosimilars are price-friendly versions of biologics — drugs used to treat a range of diseases, such as cancer, arthritis, and diabetes. Most nonbiologic drugs have...

  • Here are 5 tips to make your biotech startup leaner

    Building a biotechnology startup is a lot like getting a private university education: To make progress, you have to get past the high-cost barrier to entry. First and foremost, biotech requires expensive clinical studies and the use of state-of-the-art manufacturing facilities. In fact, major pharmaceutical companies spend at least US$4-billion to develop a single drug. That’s not pocket change for the typical entrepreneur. But even biotech startups spend between US$20 000 and US$50 000 per patient on direct clinical trials. And with most Phase II trials requiring at least 200 people for each study, the costs quickly add up. In addition...